Study #2020-1119
Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination with Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes
MD Anderson Study Status
Not Accepting
Treatment Agent
APR-548 + Azacitidine
Description
Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.
Information and next steps
Disease:
MDS, Myelodysplastic Syndromes
Study phase:
I
Physician name:
Guillermo Garcia-Manero
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.